» Articles » PMID: 33259899

A Novel Long Non-coding RNA RP11-286H15.1 Represses Hepatocellular Carcinoma Progression by Promoting Ubiquitination of PABPC4

Overview
Journal Cancer Lett
Specialty Oncology
Date 2020 Dec 1
PMID 33259899
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is a malignancy found at high frequency around the world. Unfortunately, the scarcity of effective early diagnostic methods invariably results in poor outcomes. Long noncoding RNAs (lncRNAs) are known to regulate the progression of hepatocellular carcinoma (HCC). A novel lncRNA RP11-286H15.1(OTTHUMG00000186042) has been identified and associated with HCC; however, the potential role of RP11-286H15.1 in HCC remains undefined. The transcript abundance of RP11-286H15.1 in 80 pairs of HCC samples and cell lines was evaluated by qRT-PCR analysis. The functional role of RP11-286H15.1 in HCC was tested in vivo and in vitro. The mechanisms underlying the role of RP11-286H15.1 in HCC were explored by RNA pulldown, transcriptome sequencing, and RNA immunoprecipitation (RIP), ubiquitination and fluorescence in situ hybridization (FISH) assays as well as Western blot analysis. The qRT-PCR and FISH assays revealed that RP11-286H15.1 was significantly decreased in HCC, and implied a shorter survival time. RP11-286H15.1 overexpression inhibited HCC cell proliferation and metastasis in vitro and in vivo, whereas RP11-286H15.1 knockdown produced the opposite results. Furthermore, we confirmed that RP11-286H15.1 (620-750 nucleotides) binds to poly(A) binding protein 4 (PABPC4) and promotes its ubiquitination, thus, reducing the stability of TRIM37 and CDC27 mRNAs. Our study demonstrates that a novel lncRNA, RP11-286H15.1, represses HCC progression by promoting PABPC4 ubiquitination. These findings highlight potential therapeutic targets for HCC.

Citing Articles

Aberrantly Expressed tRNA-Val Fragments Can Distinguish Canine Hepatocellular Carcinoma from Canine Hepatocellular Adenoma.

Hashimoto S, Hasan M, Arif M, Nozaki N, Husna A, Furusawa Y Genes (Basel). 2024; 15(8).

PMID: 39202384 PMC: 11353709. DOI: 10.3390/genes15081024.


Role of microRNA-494 in tumor progression.

Maharati A, Akhlaghipour I, Taghehchian N, Yazdi Z, Moghbeli M Am J Transl Res. 2023; 15(11):6342-6361.

PMID: 38074823 PMC: 10703645.


LINC02086 promotes cell viability and inhibits cell apoptosis in breast cancer by sponging miR-6757-5p and up-regulating EPHA2.

Han X, Shi F, Guo S, Li Y, Wang H, Song C World J Surg Oncol. 2023; 21(1):371.

PMID: 38008720 PMC: 10680215. DOI: 10.1186/s12957-023-03245-w.


is a key factor regulating reticulophagy-mediated ferroptosis in hepatocellular carcinoma.

Bi T, Lu Q, Pan X, Dong F, Hu Y, Xu Z Cell Cycle. 2023; 22(17):1900-1920.

PMID: 37603831 PMC: 10599178. DOI: 10.1080/15384101.2023.2249302.


Lnc-ZEB2-19 Inhibits the Progression and Lenvatinib Resistance of Hepatocellular Carcinoma by Attenuating the NF-κB Signaling Pathway through the TRA2A/RSPH14 Axis.

Cao M, Ren Y, Li Y, Deng J, Su X, Tang Y Int J Biol Sci. 2023; 19(12):3678-3693.

PMID: 37564197 PMC: 10411463. DOI: 10.7150/ijbs.85270.